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Abstract
The peroxisome proliferator-activator receptor PPARc plays an essential role in vascular biology, modulating macrophage
function and atherosclerosis progression. Recently, we have described the beneficial effect of combined activation of the
ghrelin/GHS-R1a receptor and the scavenger receptor CD36 to induce macrophage cholesterol release through
transcriptional activation of PPARc. Although the interplay between CD36 and PPARc in atherogenesis is well recognized,
the contribution of the ghrelin receptor to regulate PPARc remains unknown. Here, we demonstrate that ghrelin triggers
PPARc activation through a concerted signaling cascade involving Erk1/2 and Akt kinases, resulting in enhanced expression
of downstream effectors LXRa and ABC sterol transporters in human macrophages. These effects were associated with
enhanced PPARc phosphorylation independently of the inhibitory conserved serine-84. Src tyrosine kinase Fyn was
identified as being recruited to GHS-R1a in response to ghrelin, but failure of activated Fyn to enhance PPARc Ser-84 specific
phosphorylation relied on the concomitant recruitment of docking protein Dok-1, which prevented optimal activation of
the Erk1/2 pathway. Also, substitution of Ser-84 preserved the ghrelin-induced PPARc activity and responsiveness to Src
inhibition, supporting a mechanism independent of Ser-84 in PPARc response to ghrelin. Consistent with this, we found that
ghrelin promoted the PI3-K/Akt pathway in a Gaq-dependent manner, resulting in Akt recruitment to PPARc, enhanced
PPARc phosphorylation and activation independently of Ser-84, and increased expression of LXRa and ABCA1/G1.
Collectively, these results illustrate a complex interplay involving Fyn/Dok-1/Erk and Gaq/PI3-K/Akt pathways to transduce in
a concerted manner responsiveness of PPARc to ghrelin in macrophages.
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Introduction
Ghrelin is an acetylated 28 amino acid hormone initially
identified from the stomach, which induced the release of growth
hormone (GH) from the pituitary and regulates food intake,
energy homeostasis and adiposity [1,2]. Cellular signals carried by
ghrelin are transduced by the growth hormone secretagogue
receptor 1a (GHS-R1a), a 7-transmembrane-domain G-protein-
coupled receptor mainly expressed in hypothalamus and pituitary
[3]. In somatotroph cells, the activation of GHS-R1a by ghrelin
induces GH release through enhanced phospholipase C activity,
protein kinase C and intracellular calcium mobilization [4].
However, in concordance with the peripheral distribution of
GHS-R1a, including vascular endothelium, myocardium and
monocytes [5–7], emerging evidence indicates that ghrelin and its
receptor have a variety of GH releasing-independent cardiovas-
cular and anti-inflammatory activities [8–10]. Attempts to
elucidate the peripheral cardiovascular effects of ghrelin have
identified several signaling mechanisms involving both classical G-
protein effectors and G-protein independent pathways, highlight-
ing the complexity of GHS-R1a activation [11–14]. In endothelial
cells, ghrelin has been shown to modulate Erk, Akt kinase, nitric
oxide synthase and nuclear factor kappa B activities, in the
regulation of cell proliferation and vascular inflammation
[7,12,15–17]. Ghrelin also inhibited proliferation of human aortic
smooth muscle cells through a cAMP/PMA activation pathway
[18]. Given such complexity in GHS-R1a signaling, the molecular
mechanisms underlying ghrelin downstream effects on macro-
phage biology have not yet been described.
Macrophages are central players for key early events in
atherogenesis. The accumulation of oxidized cholesterol-rich low
density lipoproteins (oxLDL) into the intima and their subsequent
uptake by monocyte-derived macrophages, leads to the formation
of the characteristic cholesterol-loaded foam cells. Oxidized fatty
acids and oxysterols generated as a result of oxLDL uptake by
macrophages, act as ligands for the nuclear receptors peroxisome
proliferator-activated receptor c (PPARc) and liver X receptor a
(LXRa) respectively, which are part of a metabolic cascade
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apolipoprotein E and ATP-binding cassette (ABC) sterol trans-
porters involved in cholesterol efflux [19–21]. An important role of
PPARc in exerting overall beneficial anti-atherosclerotic effects
has been provided with the ability of thiazolidinediones, identified
as high affinity synthetic PPARc agonists with potent insulin
sensitizing properties, to reduce macrophage intracellular choles-
terol levels [22–25].
We recently reported that a growth hormone secretagogue
which interacts with both the GHS-R1a receptor and the
scavenger receptor CD36 markedly decreased plaque formation
in apoE-null mice fed a high fat diet, a condition known to
promote atherosclerosis [26,27]. Our studies have further
demonstrated that these beneficial effects were dependent on the
transcriptional activation of PPARc and enhanced expression of
LXRa and ABCA1/G1 transporters, thereby leading macrophag-
es to shunt excess cholesterol into the HDL reverse pathway [26].
The metabolic cascade involving PPARc and LXRa was proposed
as an attempt by the macrophage to enhance its ability to remove
oxLDL from the vessel wall acting through the positive regulation
of CD36. Although the role of CD36 receptor in mediating
oxLDL uptake and PPARc activation in macrophages is
recognized, the cellular events by which GHS-R1a activation
might regulate PPARc activity and downstream gene expression
remain unknown.
To understand how ghrelin and GHS-R1a might impact
cholesterol metabolism in macrophages, we therefore investigated
the intracellular signal transduction pathways involved in GHS-
R1a activation and the ability of ghrelin to regulate PPARc
activity and dependent gene expression. Our results identify an
intricate and complex kinase signaling interplay which is triggered
by ghrelin and modulates in a concerted manner PPARc-
dependent transcriptional competence in macrophages.
Results
Ghrelin Stimulates the PPARc-LXRa-ABC Transporters
Pathway in THP-1 Macrophages
We previously reported that hexarelin, a GH secretagogue that
interacts with both CD36 and GHS-R1a receptors, activated the
PPARc-LXRa-ABCA1/G1 transporter pathway in macrophages
[26]. To evaluate the role of the GHS-R1a receptor in the
regulation of cholesterol efflux effectors in the macrophage, we
treated PMA-differentiated THP-1 macrophages with increasing
doses of ghrelin (1, 10, and 100 nM), and measured the expression
of components of the PPARc-LXRa-ABC pathway. Our results
showed that ghrelin elicited a dose-dependent increase in LXRa,
ABCA1, and ABCG1 mRNA expression, as well as for GHS-R1a,
with values reaching 1.8-, 1.7-, 2.2-, and 2.1-fold respectively,
when treated with 100 nM ghrelin compared to untreated
differentiated cells (Figs. 1A and B). These changes were paralleled
with enhanced LXRa and ABCG1 protein levels (Fig. 1C).
Whereas PPARc gene expression was not significantly changed by
ghrelin, a 3.5-fold increase in protein levels was observed,
probably reflecting a reduced turnover of PPARc, as also reported
in THP-1 cells treated with GH secretagogues [26,27]. CD36
mRNA and protein levels remained unchanged following ghrelin
treatment, as opposed to macrophages treated with the PPARc
agonist rosiglitazone (figs. 1A and B, and data not shown). This
distinct regulation of CD36 was also reported in response to
hexarelin and shown to depend on a selective recruitment of
PPARc to CD36 promoter in differentiated macrophages [26,27].
To ensure whether PPARc was required to mediate the increase in
gene expression to ghrelin, we used a shRNA lentiviral-knockdown
approach to impair PPARc expression as described [28]. We
found that silencing PPARc expression in THP-1 cells impaired
the induction of LXRa and ABCA1 gene expression normally
observed with ghrelin (Fig. 1D), in line with an essential role of
PPARc in mediating responsiveness to ghrelin in macrophages.
These results indicate that activation of the GHS-R1a receptor by
ghrelin stimulates the expression of components of the PPARc-
LXRa-ABC pathway in THP-1 macrophages.
Ghrelin Promotes PPARc Transcriptional Activity through
the AF-1 Domain
To directly assess whether ghrelin signals to activate PPARc,w e
used a luciferase reporter assay in which human embryonic kidney
293 cells were transfected in presence or absence of the GHS-R1a
receptor, along with a Gal4-PPARc expression plasmid and a
UAStkLuc reporter. As shown in figure 2A, cells expressing GHS-
R1a showed a 1.7-fold increase in PPARc transcriptional activity
in response to ghrelin when compared to untreated cells. To
determine which part of PPARc conferred such responsiveness
to ghrelin, we used truncated ABCD and CDEF constructs of
PPARc in which the transcriptional active domains AF-2 and
AF-1 were respectively removed. We found that ghrelin promoted
the activity of the Gal4-ABCDc to a similar extent as to the full-
length receptor, whereas no significant activation of the CDEFc
construct was observed (Fig. 2B). These data suggest that GHS-
R1a activation by ghrelin increases the ligand-independent activity
of PPARc through activation of its N-terminal AF-1 domain.
Ghrelin Promotes PPARc1 Phosphorylation Independent
of Serine 84 in Macrophages
It has been reported that phosphorylation of AF-1 conserved
serine 84 of PPARc1 and Ser-112 of PPARc2 by MAPK/Erk
resulted in PPARc transcriptional inhibition in adipocytes [29,30].
Consequently, we tested the implication of this site in the
modulation of PPARc activity by ghrelin, both in transfected
293 cells and in THP-1 macrophages. As expected, mutation of
Ser-84 with alanine (PPARcS84A) removed the inhibition
potential of this site on PPARc1 activation in 293 cells treated
or not with rosiglitazone (Fig. 2C). Interestingly, a similar
enhancement in PPARcS84A activity was observed in cells
transfected with GHS-R1a and treated with ghrelin, reaching a
near 3-fold increase in response to 100 nM ghrelin compared to
2.2-fold in cells transfected with wt PPARc (Fig. 2C), indicating
that PPARcS84A was responding to ghrelin, therefore precluding
a role of PPARc Ser-84 in mediating ghrelin responsiveness. To
test the role of Ser-84 in the response of macrophages to ghrelin,
we performed immunoblot analysis using a PPARc phospho-Ser-
84 specific antibody on cell extracts immunoprecipitated with an
anti-PPARc. No increase in phosphorylation was detected on Ser-
84 site of PPARc in response to ghrelin (Fig. 2D). However, when
using a total phospho-serine antibody, we observed that ghrelin
strongly stimulated in a time- and dose-dependent manner the
phosphorylation of PPARc in THP-1 cells. These results indicate
that ghrelin might induce kinase signaling pathways through the
GHS-R1a receptor, which promote PPARc phosphorylation
independently of Ser-84.
The Effects of Ghrelin on PPARc Are Independent of the
Epidermal Growth Factor Receptor
A wide range of extracellular signals are transduced by G-
protein-coupled receptors (GPCR), and among others, it has been
proposed that for several GPCR agonists, the epidermal growth
factor receptor (EGFR) can be used as an intermediate to trigger
Ghrelin Signaling to PPARc
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role of EGFR has not been clearly defined in the peripheral
actions of ghrelin, we tested whether EGFR was involved in
GHS-R1a-mediated activation of MAPK by ghrelin in macro-
phages using the EGFR selective AG1478 inhibitor. We found
that whereas a short time exposure of 5 minutes of THP-1
macrophages to ghrelin induced Erk activation in a manner partly
dependent on EGFR activity, no significant effect of EGFR
inhibition was observed with longer treatment periods, such as 15
and 30 minutes (Fig. 3A and data not shown), suggesting a mild
and transient role of EGFR in ghrelin responsiveness of
macrophages. However, whether this apparent contribution of
EGFR was meaningful, it had no significant effect on PPARc
activation by ghrelin (Fig. 3B), and both total serine and Ser-84
Figure 1. Ghrelin stimulates the PPARc-LXRa-ABC pathway in THP-1 macrophages. (A) RT-PCR analysis of PMA-differentiated THP-1
macrophages treated or not with 100 nM ghrelin 48 h. Representative images are shown for the indicated genes. (B) Relative mRNA expression of
THP-1 cells treated with increasing doses of ghrelin for 48 h. Rosiglitazone was used as a positive control of PPARc activation. Data are presented as
fold changes (6SEM) compared with undifferentiated cells, obtained from three to four separate experiments. (C) Representative immunoblot
analysis of THP-1 cells treated with 10 nM ghrelin for 48 h. Relative fold changes are indicated. (D) PPARc is required to mediate gene activation to
ghrelin. Real-time gene expression analysis in THP-1 cells treated with 10 nM ghrelin for 48 h. PPARc expression was silenced by infecting cells with a
lentiviral-carrying shPPARc and compared to a negative control shRNA. Results are normalized to GAPDH expression.
doi:10.1371/journal.pone.0007728.g001
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significantly affected upon EGFR inhibition (Fig. 3C). In contrast,
the EGFR inhibitor completely abolished the increase in PPARc
phosphorylation induced by treating cells with TNF-a, a cytokine
reported to promote MAPK activation and suppression of PPARc
activity in pre-adipocytes [33]. These results suggest the existence
of other mechanisms independent of EGFR by which GHS-R1a
regulates PPARc activity in macrophages.
Activation and Recruitment of Fyn Tyrosine Kinase to the
GHS-R1a Receptor
Non-receptor Src-family tyrosine kinases have been reported to
directly interact with GPCR receptors [31,34]. Src tyrosine kinase
signaling has also been shown to play a central role in
proatherogenic responses mediated by oxidized lipid metabolites
in vascular smooth muscle cells implicated in atherosclerotic lesion
formation [35,36]. In an attempt to further investigate GHS-R1a
signaling to PPARc, the contribution of Src-family kinases as
downstream effectors of GHS-R1a signaling was evaluated. Our
findings revealed a strong time-dependent increase in response to
ghrelin of Src tyrosine 418 phosphorylation (pY418), a hallmark of
Src-related kinase activation, reaching nearly a 4-fold induction
compared to untreated THP-1 cells (Fig. 4A). This activation
was impaired in cells treated with the Src inhibitor PP2, a
pyrazolopyrimidine derivative highly selective for Src, Fyn and
Yes tyrosine kinases at the concentration used, whereas pretreat-
ment with the PI3-K inhibitor LY294002 had minor effects.
In line with such activation of members of the Src family in
response to ghrelin and according to the integrative role of Fyn in
the metabolic regulation of lipids as recently described in peripheral
tissues [37], we determined whether Fyn kinase was involved in the
transduction of ghrelin signal in macrophages. Immunoprecipita-
tionand Westernanalysis of activated FyninTHP-1cells revealed a
strong time-dependent increase in Fyn tyrosine phosphorylation in
response to ghrelin (Fig. 4B). To further ascertain the role of Fyn in
the activation of GHS-R1a by ghrelin, we found that ghrelin
induced a stronger recruitment of activated Fyn kinase to the GHS-
R1a in a time- and dose-dependent manner in THP-1 cells,
reaching a 5-fold increase within 30 min of treatment (Fig. 4C).
Addition of the GHS-R1a antagonist (D-Lys
3)-GHRP-6 completely
abolished the recruitment of activated Fyn to the GHS-R1a
receptor (Fig. 4D). These results identify Fyn kinase as a signaling
intermediate in the activation of the GHS-R1a receptor.
Figure 2. Ghrelin induces PPARc activation and phosphorylation independently of serine-84. (A) Ghrelin promotes PPARc activity in 293
cells transfected with a UAStkLuc reporter plasmid in the presence of GHS-R1a and Gal4 fusion of full-length PPARc1 expression plasmids. Transfected
cells were treated with 10 nM ghrelin or 1.4 mM rosiglitazone for 20 h and harvested for luciferase activity. Values are normalized to b-galactosidase
activity and expressed as fold changes in luciferase activity compared with untreated cells expressing GHS-R1a. Error bars represent the mean 6SEM
of triplicate values derived from at least three independent experiments. (B) Similar as in (A) except that a truncated ABCDc construct lacking the
ligand binding domain, or a CDEFc construct lacking the N-terminal region were used. (C) Activation of PPARc by ghrelin is independent of serine 84.
293 cells were transfected as in (A) with an expression vector for Gal4-PPARc or Gal4-PPARcS84A. Cells were treated with ghrelin as indicated or with
1.4 mM rosiglitazone for 20 h. (D) Phosphorylation of PPARc in serum-deprived differentiated THP-1 cells treated with increasing doses of ghrelin for
the indicated time. Cell extracts were immunoprecipitated with an antibody against PPARc and analyzed by immunoblot using antibodies against
phospho-serine residue or phospho-specific to PPARc serine-84. Samples were normalized with a different anti-PPARc antibody.
doi:10.1371/journal.pone.0007728.g002
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PPARc Activity
Src tyrosine kinases have been involved in the ability of GPCRs
to induce Erk1/2 activity [31]. Since our results suggest a role for
Fyn kinase in GHS-R1a signaling, we assessed the impact of Src/
Fyn inhibition on Erk1/2 activation in response to ghrelin.
Interestingly, in the presence of PP2 inhibitor, THP-1 macro-
phages showed a respective 2- and 3-fold increase in Erk1/2
phosphorylation in response to 15 and 30 minute treatment with
ghrelin, compared to cells not treated with PP2 (Fig. 5A). In
addition, this activation of Erk1/2 upon Src/Fyn inhibition
correlated with an increase in PPARc phosphorylation, more
specifically at Ser-84, in THP-1 cells treated with ghrelin in the
presence of PP2 inhibitor (Fig. 5B). In line with the inhibitory role
of Ser-84 phosphorylation on PPARc activity, we next tested the
influence of Src/Fyn inhibition on ghrelin-mediated activation of
PPARc. As shown in figure 5C, PPARc transcriptional response to
GHS-R1a expression and activation was strongly impaired in the
presence of PP2 inhibitor, an effect that required the integrity of
Ser-84. A similar inhibitory effect of PP2 was also observed on the
activation of PPARc to thiazolidinedione ligands (data not shown),
supporting the inhibition potential of Erk on PPARc response to
ligands [38]. To ascertain the specific implication of Fyn kinase in
modulating PPARc Ser-84 phosphorylation by Erk1/2, we found
that ectopic expression of Fyn in the presence of GHS-R1a in 293
cells caused a strong inhibition of Erk1/2 phosphorylation, which
correlated with a time-dependent decrease of PPARc Ser-84
phosphorylation in response to ghrelin (Fig. 5D). Altogether, our
results emphasize a role for Fyn activation to restrain the
inhibitory potential of Erk1/2 on PPARc Ser-84, therefore
allowing a maximal response of PPARc to ghrelin.
Ghrelin Promotes Activation of the Docking Protein
Dok-1 and Its Recruitment to Fyn Kinase
The apparent activating role of Fyn on PPARc activity through
a negative regulation of Erk1/2 is rather intriguing and suggests
that other components may modulate Src/Fyn response to
ghrelin. One interesting candidate is the docking protein Dok-1
which was described as a negative regulator of the Ras/MAPK
pathway and mitogenic signaling in immune cells [39,40]. Indeed,
Dok-1 becomes tyrosine phosphorylated following activation of
receptor and cytoplasmic tyrosine kinases, including Src kinases
Lyn and Fyn [41], and overexpression of Dok-1 was shown to
inhibit Erk1/2 activation induced by Fyn in 293 cells [42]. To
determine the possible implication of Dok-1 in the inhibitory effect
of Fyn on Erk1/2 activity, we examined the phosphorylation status
of Dok-1 and its ability to interact with Fyn kinase in response to
ghrelin. Using 293 cells transfected with Dok-1 in the presence of
GHS-R1a, we found that phosphorylation of Dok-1 was increased
in response to ghrelin (Fig. 5E). In addition, this activated Dok-1
was co-precipitated with phosphorylated Fyn in the same
conditions, indicating that ghrelin promotes activation of Dok-1
and Fyn recruitment. Both tyrosine phosphorylation of Dok-1 and
recruitment of activated Fyn were completely inhibited in the
presence of PP2 inhibitor and were shown to be dependent on
Dok-1 Tyr-146 (Fig. 5E), a phosphorylation site involved in the
ability of Dok-1 to inhibit Erk1,2 [43]. These observations on the
association between Fyn and Dok-1 were also reproduced in THP-
1 macrophages. Indeed, endogenous Dok-1 was shown to be
increasingly tyrosine phosphorylated and recruited to activated
Fyn in response to ghrelin, both of which being abolished by the
PP2 inhibitor (Fig. 5F). Taken together, these findings suggest that
the activation and recruitment of Fyn kinase to GHS-R1a in
response to ghrelin, promotes the recruitment of Dok-1, thus
forming a repressive complex by which Erk1/2 activation and its
inhibitory effect on PPARc activity through Ser-84 phosphoryla-
tion is minimized in macrophages.
The PI3-K/Akt Pathway Promotes PPARc Activation by
Ghrelin
Our interpretation on the inhibition potential of Fyn to restrain
Erk1/2 activity through Dok-1 recruitment, therefore relieving
Erk1/2 inhibition on PPARc activity, may not fully account for
PPARc activation by ghrelin. This is especially emphasized by the
fact that ghrelin could enhance Erk1/2 activity in THP-1 cells,
Figure 3. The effects of ghrelin on PPARc are independent of
the EGF receptor. (A) Phosphorylation of Erk1/2 in differentiated THP-
1 cells serum-deprived for 16 h and treated with 5 mM of the EGFR
inhibitor AG1478 for 30 min before incubation with 10 nM ghrelin for 5
and 15 min. The lysates were analyzed by immunoblot using a
phospho-Erk1/2 antibody and normalized with an anti-Erk1/2 antibody.
(B) Effect of EGFR inhibition on PPARc activity using 293 cells
transfected with UAStkLuc reporter along with Gal4-PPARc and GHS-
R1a plasmids, and then treated with 10 nM ghrelin with or without
5 mM EGFR inhibitor AG1478 for 20 h before harvested for luciferase
assay. (C) Phosphorylation of PPARc in THP-1 cells treated as in (A) or
with 1 mM TNFa for 15 min. Cell extracts were immunoprecipitated with
an antibody against PPARc and analyzed by immunoblot with anti-
phospho-serine and anti-PPARc pSer-84 antibodies.
doi:10.1371/journal.pone.0007728.g003
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phosphorylation of PPARc independent of Ser-84 (Fig. 5A and B).
This prompted us to consider whether the PI3-K/Akt signaling
pathway could be involved in the ghrelin-mediated activation of
PPARc. As such, we observed that treatment of THP-1
macrophages with ghrelin increased in a time-dependent manner
the phosphorylation of Akt and of p85 regulatory subunit of PI3-
K, indicating an activation of the PI3-K/Akt pathway (Fig. 6A).
These responses did not seem to be mediated by Src-related
kinases, as the PP2 inhibitor had no significant effect. Further
supporting a role for the PI3-K/Akt pathway, we found that
pretreatment with the PI3-K inhibitor LY294002, prior to
stimulation with ghrelin, completely abolished the effects of
ghrelin on PPARc activity (Fig. 6B) and serine phosphorylation
(Fig. 6C). Also, transient co-expression of Akt with a constitutively
active p110a PI3-K in 293 cells, which results in potent activation
of Akt [44], led to a 1.6- and 1.7-fold increase in the activity of
PPARc and PPARcS84A respectively, compared to mock-
transfected cells (Fig. 6D), reaching values observed with ghrelin
activation of GHS-R1a (Figs. 2C and 5C). This activation of
PPARc by the PI3-K/Akt pathway also correlated with an
enhanced recruitment of Akt to PPARc in response to ghrelin, as
tested with the PPARc2 isoform, which along with PPARc1, is
also expressed in macrophages (Fig. 6E). Neither PPARc1 Ser-84,
nor its conserved Ser-112 in PPARc2, seems to behave as a critical
determinant in PPARc response to ghrelin-activated PI3-K/Akt
pathway (Figs. 6C and E). Altogether, these results emphasize a
predominant role of the PI3-K/Akt pathway in mediating PPARc
activation by ghrelin.
Activation of Gaq Subunit Is Required for Ghrelin-Induced
Akt and PPARc Activation
Based on recent reports that have implicated the Gq proteins in
the central effects of ghrelin on GHS-R1a signaling in pituitary
cells [45,46], and on their possible convergence with the Akt
pathway in endothelial cells [16], we wanted to determine whether
the activation of PPARc by ghrelin was dependent on G-protein
signaling pathway in macrophages. As shown in figure 6F,
pretreatment of THP-1 cells with the Gaq inhibitory peptide
GP-Antagonist-2A completely abrogated the activation of Akt by
ghrelin. Also, Gaq inhibition resulted in the suppression of the
transcriptional response of PPARc to ghrelin (Fig. 6G), whereas
PKC inhibitors, such as staurosporine and GF109203X, had no
significant effects (data not shown). These data identify the a
subunit of Gq protein as a signaling intermediate of the GHS-R1a
to activate the Akt pathway and PPARc transcription potential in
macrophages.
The PI3-K/Akt Pathway Plays a Critical Role in the
Activation of the PPARc-LXRa-ABC Metabolic Cascade by
Ghrelin
In order to establish whether activation of the PI3-K/Akt
pathway was involved in the upregulation of PPARc-dependent
gene expression, we tested the effects of the PI3-K inhibitor
LY294002 on the expression profile of downstream effectors, such
as LXRa and ABC sterol transporters in THP-1 macrophages.
Our results indicate that the increased levels observed in LXRa,
ABCA1 and ABCG1 expression upon treating cells with ghrelin
were strongly impaired with the inhibition of PI3-K (Fig. 7A).
Similarly, these effects were paralleled with decreases in PPARc,
LXRa, and ABCG1 protein levels (Fig. 7B). These findings suggest
a prominent role of the PI3-K/Akt pathway in mediating ghrelin
responsiveness of macrophages to activate the PPARc-LXRa-
ABC metabolic cascade.
Discussion
PPARc plays a central role in coordinating the macrophage
response to lipid loading through a transcriptional cascade
involving LXRa and the ABC transporters A1 and G1 [19–21].
Figure 4. Induced recruitment and activation of Fyn kinase to the GHS-R1a receptor by ghrelin. (A) Ghrelin activates Src-related kinases.
Differentiated THP-1 cells were serum-deprived for 16 h and incubated with 1 mM Src-related kinase inhibitor PP2 or 10 nM PI3-K inhibitor LY-294002
for 30 min before incubation with 10 nM ghrelin for the indicated times. The lysates were then analyzed by immunoblot with an anti-phospho-specific
to Src Tyr-418, the activation loop site, and loading was monitored with a b-actin antibody. (B) Ghrelin promotes Fyn activation in THP-1 macrophages.
Cells were treated as in (A) and extracts were immunoprecipitated with an antibody against Fyn, and analyzed by immunoblot using anti-Src-pY418
and anti-Fyn antibodies. (C) Fyn is recruited to the GHS-R1a receptor and activated by ghrelin. THP-1 cells were treated similar as in (A) and
immunoprecipitation was carried out with an antibody against GHS-R1a, and analyzed by immunoblot using anti-Src-pY418 and anti-Fyn antibodies.
Samples were normalized with an anti-GHS-R1a antibody. (D) Effect of GHS-R1a inhibition on Fyn recruitment and activation. Serum deprived THP-1
cells were pretreated with 100 nM D-Lys
3-GHRP-6 for 30 min, followed by incubation with 10 nM ghrelin for 30 min, and then analyzed as in (C).
doi:10.1371/journal.pone.0007728.g004
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shown to exert beneficial anti-atherosclerotic actions by promoting
activation of the PPARc-LXRa-ABC pathway and cholesterol
efflux [22–25]. Consequently, modulation of PPARc activity is
critical to the control of cholesterol metabolism in macrophages
and atherosclerotic vascular lesion progression. Emerging evidence
suggests that ghrelin has important and beneficial effects on the
vascular system, by ameliorating endothelial dysfunction [16,47]
and inhibiting proliferation of aortic smooth muscle cells [18].
However, ghrelin’s action on the macrophage is still not well
defined. In line with our previous work, which described a role for
scavenger CD36 and GHS-R1a/ghrelin receptors to regulate
cholesterol efflux in macrophages through a PPARc-dependent
pathway [26,27], this study identifies a complex signaling pathway
that, upon activation of GHS-R1a receptor with ghrelin, results in
the enhancement of PPARc transcriptional activity and subse-
Figure 5. The ghrelin-induced PPARc activation involves a negative regulation of Erk through Fyn/Dok-1 interaction. (A) Src
inhibition increases Erk1/2 activity in differentiated THP-1 cells serum-deprived for 16 h and incubated with 1 mM PP2 for 30 min before incubation
with 10 nM ghrelin for 2 to 30 min. The lysates were analyzed by immunoblot with antibodies specific to phospho-Erk1/2 and total Erk1/2. (B)
Phosphorylation of PPARc Ser-84 is increased by Src inhibition in THP-1 cells. Cells were treated as in (A), and lysates were immunoprecipitated with
an antibody against PPARc and analyzed by immunoblot using antibodies against phospho-serine, PPARc pSer-84, and total PPARc.( C) The PPARc
S84A mutant is insensitive to Src inhibition. 293 cells were transfected with UAStkLuc reporter in absence or presence of GHS-R1a, and with Gal4-
PPARc (left) or Gal4-PPARcS84A (right) plasmids. Cells were then treated with 10 nM ghrelin with or without 1 mM PP2 for 20 h, and harvested for
luciferase assay. Normalized values are presented as fold changes 6 SEM compared with untreated cells in presence of GHS-R1a. (D) Expression of
Fyn inhibits Erk1/2 activity and PPARc Ser-84 phosphorylation in the presence of ghrelin. 293 cells were transfected with GHS-R1a, Fyn and PPARc
expression plasmids, and then treated with 10 nM ghrelin for 5 and 15 min. Cell lysates were immunoblotted with the indicated antibodies. (E)
Ghrelin promotes activation of Dok-1 and its recruitment to Fyn. 293 cells were transfected with Fyn and GHS-R1a expression plasmids in presence of
Dok-1 or its inactive Y146F mutant, and treated with 10 nM ghrelin for the indicated time with or without 1 mM PP2. Immunoprecipitation was
carried out with an antibody against HA and analyzed by immunoblot using anti-Src pTyr-418, anti-Fyn, anti-phospho-tyrosine (pTyr) and anti-Dok-1
antibodies. (F) Ghrelin promotes the recruitment of Dok-1 to Fyn in THP-1 macrophages. Cells were treated as in (A) and the lysates were
immunoprecipitated with an antibody against Dok-1 and analyzed by immunoblot using the indicated antibodies.
doi:10.1371/journal.pone.0007728.g005
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modulation of PPARc activity implicates modification of its
phosphorylation status through the interplay of two signaling
pathways, one being mediated by Fyn/Dok-1/Erk1/2, which
mainly restrains the inhibition potential of PPARc serine 84/112,
whereas the second involves Gaq/PI3-K/Akt that promotes
PPARc activation. Therefore, our findings identify ghrelin as a
novel regulator of PPARc activation via GHS-R1a-mediated
concerted pathways in macrophages.
Members of the MAP kinase family have been implicated in the
regulation of PPARc phosphorylation and activity in response to
external signals, such as platelet derived growth factor (PDGF),
epidermal growth factor (EGF), and insulin [29,48,49]. In
particular, phosphorylation of PPARc1/2 at conserved MAPK
consensus position 84/112 is well known to reduce the
transcriptional response of PPARc to activating ligands and
mitogens in adipocytes, leading to inhibition of cell differentiation
and adipogenesis [29,30,48]. Genetic studies are also consistent
with a role of PPARc Ser-112 in fat metabolism and glucose
homeostasis, as S112A knock-in mice exhibit increased PPARc
activity with protective effects from obesity-associated insulin
resistance [50]. The present study demonstrates that the positive
effect of ghrelin on PPARc transcriptional activation is associated
with an increase in PPARc phosphorylation, which is not
dependent on Ser-84, even if ghrelin promoted the activation of
Erk. In trying to understand the molecular basis for such ligand-
independent activation of PPARc, we found that GHS-R1a
efficiently recruited and activated the Src kinase Fyn in THP-1
macrophages treated with ghrelin. This specific recruitment and
activation of Fyn through GHS-R1a restrained Erk1/2 activation
and PPARc phosphorylation on Ser-84, resulting in the release of
Ser-84 inhibitory potential. Recent evidence has provided a role
Figure 6. Positive regulation of PPARc activity by ghrelin involves the PI3-K/Akt pathway in macrophages. (A) Ghrelin induces the PI3-
K/Akt pathway in macrophages. Serum-starved THP-1 cells were treated with 10 nM ghrelin with or without 1 mM PP2 for the indicated times prior to
Western analysis for phosphorylated Akt and PI3-K p85 subunit. (B) The PI3-K/Akt pathway is required to activate PPARc by ghrelin. 293 cells were
transfected with a PPREtkLuc reporter and expression vectors encoding PPARc and GHS-R1a, and then treated with 10 nM ghrelin with or without
5 nM LY294002 inhibitor for 20 h. Normalized values are presented as fold changes 6 SEM compared with untreated cells. (C) PPARc
phosphorylation in THP-1 cells treated 10 nM ghrelin in absence or presence of 5 and 10 nM LY294002. Immunoprecipitation was carried out with a
PPARc antibody and then analyzed by immunoblot using anti-phospho-serine and anti-PPARc pSer-84 antibodies. (D) Akt promotes PPARc activity
independently of Ser-84. 293 cells were transfected with a UAStkLuc reporter and expression vector encoding PPARc1 or the S84A mutant, in
presence or absence of GHS-R1a. Cells were also transfected with plasmids for Akt or its kinase dead K179M (KD) mutant form in presence of
constitutively active p110a subunit of PI3-K as indicated. Cells were then treated with 10 nM ghrelin or left untreated for 20 h. Normalized luciferase
values are expressed as fold changes compared with untreated cells transfected with PPARc.( E) Ghrelin induces recruitment of Akt to PPARc. 293
cells were transfected with GHS-R1a and HA-Akt encoding plasmids with either PPARc2 or PPARc2 S112A constructs. Immunoprecipitation was
carried out with a PPARc antibody and Western blot with anti-HA and anti-PPARc antibodies. (F) Protein Gaq subunit is required in Akt activation by
ghrelin in macrophages. THP-1 cells were treated as in (A) in presence or absence of 6 mM GP antagonist-2A. Cells were analyzed by Western blot for
activated Akt. (G) PPARc activation by ghrelin is dependent on Gaq as determined by luciferase assay performed as in (D) in the presence or absence
of 6 mM GP antagonist-2A.
doi:10.1371/journal.pone.0007728.g006
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function. The requirement of Fyn and other Src-family tyrosine
kinases has been demonstrated in insulin-induced fat accumulation
using Src, Yes and Fyn triple knock out embryonic fibroblasts stably
expressing PPARc2 [51]. Likewise, genetic disruption of Fyn has
recently been associated with peripheral tissue insulin sensitivity
through modulation of AMP kinase activity [37]. In line with such
potential role of Fyn to regulate adipogenesis in a context in which
PPARc is established as essential, we identify Fyn as a metabolic
regulator that modulates PPARc transcriptional potential and
downstream events in macrophages.
The Src-family tyrosine kinases are typically recognized to
activate Erk1/2 in various cells [14,31], and to our surprise,
inhibiting Src kinases with PP2 enhanced the activation of Erk1/2
by ghrelin in macrophages, resulting in increased phosphorylation
on PPARc Ser-84 and consequently decreased PPARc activity. To
further characterize the molecular basis of such inhibition of Erk by
Fyn in the context of ghrelin, we identified Dok-1 as a potent
recruiting partner of activated Fyn kinase in response to ghrelin.
Dok-1 has been reported to negatively regulate Erk1/2 for tyrosine
kinase receptors suchas the insulinreceptor, by associatingwith Src
[40]. We extend these findings to Fyn kinase, which by recruiting
Dok-1, defines a GHS-R1a/Fyn/Dok-1 signaling pathway in
macrophages, which then prevents excessive Erk1/2 activation in
the presence of ghrelin. We propose that this GHS-R1a/Fyn/Dok-
1 pathway is used to alleviate the inhibitory potential of Ser-84/112
phosphorylation on PPARc activity, therefore resulting in en-
hanced PPARc-dependent response to ghrelin. Consistent with
such repressive role of Dok-1 on macrophage PPARc activity, it
was recently reported that Dok-1 is essential to mediate adipocyte
response to insulin, by antagonizing activation of the Ras/Erk1/2
pathway that would otherwise maintain basal phosphorylation
of PPARc Ser-112 and limit its ability to promote terminal
differentiation of adipocytes [52].
Our findings that Dok-1 is used to restrain the inhibitory
potential of Erk on PPARc might not fully explain how ghrelin
achieves PPARc activation in macrophages. Signaling of ghrelin
receptor is complex and multiple pathways with frequent cross-talk
of signaling components have been described in several cell types.
Although not clearly defined for GHS-R1a receptor, the EGFR
was proposed as an intermediate partner in transducing Erk
activation by GPCRs [31]. Also, ghrelin was described to activate
cAMP-dependent protein kinase in aortic endothelial cells [15]
and several isoforms of calcium-dependent protein kinase [14,32].
Notwithstanding their potential role in transducing ghrelin
responsiveness to other cellular factors, our results indicate that
these pathways are unlikely to be involved in GHS-R1a mediated
PPARc activation in macrophages.
Interestingly, the observation that ghrelin promoted activation
of the PI3-K/Akt pathway, which then resulted in enhanced
activation of PPARc, provides a mean by which ghrelin can
initiate positive signals to PPARc in macrophages. Akt was
described to mediate ghrelin responsiveness in various cells
[11,16,53,54], and this activation was recently shown to be
dependent on both a Gai/o-protein-coupled and b-arrestin
scaffolded complex in 3T3-L1 cells [54]. In addition, expression
of an activated form of Akt was described to trigger spontaneous
adipocyte differentiation of 3T3-L1 preadipose cells [55,56], in
support of a role of Akt in regulating PPARc in fat cells. Here, we
demonstrate that the PI3-K/Akt pathway acts as a positive
regulator of PPARc function in macrophages, by promoting the
induction of the PPARc-LXRa-ABC metabolic cascade that
governs cholesterol removal from these cells. The activation of Akt
by ghrelin is a result of a distinct signaling pathway, which is
independent of Src-related activity but required Gaq coupling
to GHS-R1a receptor, emphasizing the complexity of ghrelin
signaling in macrophages.
Although PPARc was shown to be phosphorylated indepen-
dently of Ser-84 upon activation of Akt, no consensus site for Akt
has be identified in PPARc1/2, suggesting that the activation
potential of Akt on PPARc is probably indirect. Numerous
transcriptional coactivators that facilitate PPARc activity have
been described, some of which being directly regulated by Akt
[57]. For instance, we showed that PPARc can benefit from the
enhanced transcriptional potential of CREB binding protein
Figure 7. Activation of the PPARc-LXRa-ABC transcriptional
cascade by ghrelin is dependent on the PI3-K/Akt pathway. (A)
Role of the PI3-K pathway on gene expression analysis from THP-1 cells
treated with 100 nM ghrelin and 5 nM LY294002 for 48 h. Represen-
tative images and fold changes of mRNA expression are shown for the
indicated genes. (B) Immunoblot analysis of THP-1 cells treated with
ghrelin in presence or absence of 5 nM LY294002 for 48 h. Fold
changes are shown relative to untreated cells. (C) A proposed model for
the GHS-R1a-induced signaling to PPARc in macrophages. Activation of
GHS-R1a by ghrelin promotes the recruitment and activation of a Fyn/
Dok-1 complex with the subsequent decrease in Erk1/2-mediated
phosphorylation of PPARc Ser-84, restraining its inhibitory potential.
Ghrelin also activates the PI3-K/Akt pathway through a Gaq–dependent
m e c h a n i s m ,w h i c ht h e np r o m o t e sP P A R c AF-1 phosphorylation
independently of Ser-84, resulting in receptor transcriptional activation
and increase in the PPARc-LXRa-ABCA1/G1 metabolic cascade in
macrophages.
doi:10.1371/journal.pone.0007728.g007
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likely cofactor that might potentiate PPARc response to ghrelin-
activated Akt pathway. Clearly, further studies are needed to
identify the exact activation mechanism by which PPARc
responds to enhanced PI3-K/Akt pathway in macrophages, and
how this process might selectively be facilitated through cofactor
usage.
Collectively, our results establish a GHS-R1a signaling pathway
that functions to regulate PPARc transcriptional potential in
macrophages, which implicates ghrelin and GHS-R1a in the
removal of cholesterol from vascular atherosclerotic lesions. In line
with such beneficial role of macrophage GHS-R1a receptor, we
previously demonstrated the anti-atherogenic properties of
hexarelin, a hexapeptide ligand that binds to both scavenger
CD36 and GHS-R1a receptors [26,58]. Given that ghrelin also
decreases the release of proinflammatory cytokines in monocytes
and T lymphocytes from T cells and monocytes [59], our findings
raise the interesting possibility that ghrelin might have the
potential to reduce atherosclerotic lesion development, which
might represent an important mechanism for the recognized
cardiovascular protection of ghrelin observed in animal models
and humans [8–10]. In addition, it seems reasonable to speculate
that the Dok-1 mediated inhibition of Erk1/2 could also predict
the anti-atherogenic effects of ghrelin, given the high impact of
elevated MAPK pathway in atherosclerosis [60,61]. Altogether,
our findings provide a cellular basis for the peripheral actions of
ghrelin and the immediate response of PPARc-regulated pathways
that have potential important implications for the treatment of
human vascular diseases.
Methods
Plasmids Constructs
pCMX expression plasmids coding for mouse PPARc2, human
PPARc1, and Gal4- PPARcABCD (aa 1–254) have been
described previously [26]. The N-terminal truncated Gal4-
PPARcCDEF construct was generated by amplifying the aa
109-477 fragment of hPPARc1 by PCR. The PPARc1 Ser-84 to
alanine and the PPARc2 Ser-112 to alanine mutants were
generated by PCR mutagenesis and confirmed by automated
sequencing. The luciferase reporter constructs UAStkLuc and
PPREtkLuc, as well as plasmids for Akt and its inactive K179M
mutant, and for constitutively active p110a catalytic subunit of
PI3-K have been described [26,44]. Expression plasmids coding
for Fyn kinase and Dok-1 were kindly provided by M. Resh and P.
Duplay respectively.
Cell Culture
Human monocytes THP-1 cells (ATCC, Manassas, VA) were
grown in RPMI 1640 supplemented with 10% FBS. Macrophage
differentiation was initiated by the addition of 5 ng/ml phorbol
myristate acetate (PMA) in culture medium for 48–72 h. Human
embryonic kidney 293 cells were cultured in DMEM containing
5% fetal bovine serum (FBS). Treatments with rosiglitazone
(1–1.4 mM) and ghrelin (1–100 nM) were replaced with fresh
medium every 24 h.
RNA Isolation and qPCR Analysis
Total RNA was isolated from THP-1 cells using TRIzol reagent
(Invitrogen, Burlington, Ontario, Canada) and RT-PCR analysis
was done as described [62,63]. PCR products were analyzed on a
MX3000P (Stratagene, La Jolla, CA) and on gel (Alpha Innotech,
San Leandro, CA), from at least three separate experiments. All
values were normalized against GAPDH expression.
RNA Interference
To silence PPARc expression, small hairpin RNA duplexes
targeting the sequence AAAGCAAAGGCGAGGGCGATCTT
of human PPARc (shPPARc) were inserted into the pLVTH
lentiviral vector for small interfering RNA production. Viral
particles were produced in 293T cells as described [28,63], and
used to infect THP-1 macrophages. PPARc efficient knockdown
was monitored by Western analysis (data not shown).
Antibodies
Antibodies to PPARc, LXRa, Fyn, phospho-Akt (Ser-473),
phospho-p85, p85, Dok-1, and phospho-tyrosine were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to
ABCG1 were obtained from Novus Biologicals (Littleton, CO),
anti-PPARc phospho-Ser-84 from Upstate (Lake Placid, NY),
anti-Src phospho-Tyr-418 from Calbiochem (Darmstadt, Ger-
many), anti-Erk1/2 from Invitrogen (Carlsbad, CA), and anti-b-
actin from Abcam (Cambridge, MA). The anti-phospho-serine
antibody was obtained from Chemicon (Temecula, CA), and the
anti-Akt from Cell Signaling Technology (Danvers, MA). Anti-
bodies against CD36 and GHS-R1a [26,64], and HA [63,65] have
been described.
Immunoprecipitation and Immunoblotting Analysis
Immunoprecipitation and immunoblotting procedures were
done essentially as described [27,66]. Briefly, for immunoprecip-
itation assay, cells were washed in ice-cold PBS, and lysed in RIPA
buffer consisting of 1% Triton X-100, 0.5% deoxycholic acid,
0.1% sodium dodecyl sulfate (SDS), 1 mM sodium fluoride, 1 mM
sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, and
protease inhibitors (Roche, Laval, Qc) in PBS. Cell lysates were
precleared before incubation with respective antibodies and
protein A-agarose at 4uC. Immunoprecipitates were then washed
in lysis buffer, resolved by SDS-PAGE, and analyzed by
immunoblotting. For coimmunoprecipitation assay, cells lysates
were lysed in a modified RIPA containing 1% NP-40 and 0.25%
deoxycholic acid. Proteins were then resolved by SDS-PAGE and
subjected to Western analysis. Membranes were blocked with
blocking reagent (Roche) or 5% nonfat dry milk in Tris-buffered
saline, probed with selected antibodies, and signals visualized by
enhanced chemiluminescence using appropriate horseradish
peroxidase-conjugated secondary antibodies.
Luciferase Reporter Assay
For transient transfection, 293 cells were seeded in DMEM
supplemented with 5% charcoal dextran-treated FBS, and plasmid
constructs were introduced into cells using the calcium phosphate
precipitation method essentially as described [65]. Typically, 500
ng of reporter plasmid, 100 ng of nuclear receptor expression
vector, 20–100 ng pcDNA-hGHS-R1a plasmid, and 200 ng of
CMX-bgal were added per well. To activate the Akt pathway, cells
were transfected with 100 ng each of PI3-K p110a and Akt
expression vectors. After 6–8 h of transfection, cells were refed
with medium containing 1–100 nM ghrelin or 1.4 mM rosiglita-
zone for 16–20 h or left untreated. For luciferase assay, cells were
lysed in potassium phosphate buffer containing 1% Triton X-100,
and light emission was measured using a luminometer (Wallac,
Turku, Finland) after the addition of luciferin. Luciferase values
were normalized for transfection efficiency to b-galactosidase
activity of each sample, and expressed as relative fold response
compared with controls. Luciferase assays were done in triplicates
from at least three independent experiments.
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